$6.80
-0.09 (-1.31%)
Open$7.00
Previous Close$6.89
Day High$7.25
Day Low$6.79
52W High$34.25
52W Low$4.91
Volume—
Avg Volume187.4K
Market Cap12.43M
P/E Ratio—
EPS$-47.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+265.4% upside
Current
$6.80
$6.80
Target
$24.85
$24.85
$15.48
$24.85 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.16M | 3.54M |
| Net Income | -163,651 | -194,157 | -147,578 |
| Profit Margin | -3.9% | -4.7% | -4.2% |
| EBITDA | -229,901 | -240,916 | -206,498 |
| Free Cash Flow | -133,630 | -165,029 | -157,801 |
| Rev Growth | +8.4% | +2.1% | +5.7% |
| Debt/Equity | 0.23 | 0.22 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |